التفاصيل البيبلوغرافية
| العنوان: |
High-Dose Nebulized Colistin Methanesulfonate and the Role in Hospital-Acquired Pneumonia Caused by Gram-Negative Bacteria with Difficult-to-Treat Resistance: A Review |
| المؤلفون: |
Ilias Karaiskos, Aikaterini Gkoufa, Elena Polyzou, Georgios Schinas, Zoe Athanassa, Karolina Akinosoglou |
| المصدر: |
Microorganisms; Volume 11; Issue 6; Pages: 1459 |
| بيانات النشر: |
Multidisciplinary Digital Publishing Institute |
| سنة النشر: |
2023 |
| المجموعة: |
MDPI Open Access Publishing |
| مصطلحات موضوعية: |
colistin methanesulfonate, colistin, high-dose nebulized CMS, nebulizers, clinical efficacy, toxicity, nebulized 15 MIU CMS, aerolized, inhaled, high dose |
| جغرافية الموضوع: |
agris |
| الوصف: |
Hospital-acquired pneumonia, including ventilator-associated pneumonia (VAP) due to difficult-to-treat-resistant (DTR) Gram-negative bacteria, contributes significantly to morbidity and mortality in ICUs. In the era of COVID-19, the incidences of secondary nosocomial pneumonia and the demand for invasive mechanical ventilation have increased dramatically with extremely high attributable mortality. Treatment options for DTR pathogens are limited. Therefore, an increased interest in high-dose nebulized colistin methanesulfonate (CMS), defined as a nebulized dose above 6 million IU (MIU), has come into sight. Herein, the authors present the available modern knowledge regarding high-dose nebulized CMS and current information on pharmacokinetics, clinical studies, and toxicity issues. A brief report on types of nebulizers is also analyzed. High-dose nebulized CMS was administrated as an adjunctive and substitutive strategy. High-dose nebulized CMS up to 15 MIU was attributed with a clinical outcome of 63%. High-dose nebulized CMS administration offers advantages in terms of efficacy against DTR Gram-negative bacteria, a favorable safety profile, and improved pharmacokinetics in the treatment of VAP. However, due to the heterogeneity of studies and small sample population, the apparent benefit in clinical outcomes must be proven in large-scale trials to lead to the optimal use of high-dose nebulized CMS. |
| نوع الوثيقة: |
text |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| العلاقة: |
Medical Microbiology; https://dx.doi.org/10.3390/microorganisms11061459Test |
| DOI: |
10.3390/microorganisms11061459 |
| الإتاحة: |
https://doi.org/10.3390/microorganisms11061459Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.2FA361FF |
| قاعدة البيانات: |
BASE |
